Active Biotech has presented results related to the cancer project ANYARA where the effect of ANYARA was studied in combination with other established tumor therapies in experimental models of cancer
Lund, Sweden | December 10, 2008 | Active Biotech AB (NASDAQ OMX Nordic: ACTI) has presented results related to the cancer project ANYARA where the effect of ANYARA was studied in combination with other established tumor therapies in experimental models of cancer. The presentation was made at IBC’s 6th Annual Antibody Therapeutics Conference held in San Diego, USA, December 9-11.
The results1) show that ANYARA can be effectively combined with other established tumor therapies like docetaxel (Taxotere), bevacizumab (Avastin) and sunitinib (Sutent). ANYARA, combined with any of these products, had superior anti-tumor activity compared to single agent therapy.
ANYARA is presently developed primarily for the treatment of Renal Cell Cancer. A pivotal phase III study, which will encompass a total of 500 patients, is currently ongoing.
1) View the complete poster "A fusion protein between a 5T4 binding antibody fragment and an engineered superantigen (ANYARA) is a targeted immunotherapy effective alone and in combination with other cancer therapies" at www.activebiotech.com
About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on renal cancer. Positive data was reported in connection with the interim analysis in Phase II/III and from clinical Phase I trials in lung cancer, renal cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cancer and treated with ANYARA is twice the expected length. Presently, pivotal Phase III trials in patients with advanced renal cancer are under way. The primary clinical efficacy parameter from this study is overall survival and it will include a total of approximately 500 patients at about 50 clinics in Europe. ANYARA has been granted orphan-drug status by the EMEA for the indication renal cancer. Information concerning the ongoing clinical study is available at www.activebiotech.com and www.clinicaltrials.gov.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on December 10, 2008, at 08:30 a.m.
SOURCE: Active Biotech AB
Post Views: 83
Active Biotech has presented results related to the cancer project ANYARA where the effect of ANYARA was studied in combination with other established tumor therapies in experimental models of cancer
Lund, Sweden | December 10, 2008 | Active Biotech AB (NASDAQ OMX Nordic: ACTI) has presented results related to the cancer project ANYARA where the effect of ANYARA was studied in combination with other established tumor therapies in experimental models of cancer. The presentation was made at IBC’s 6th Annual Antibody Therapeutics Conference held in San Diego, USA, December 9-11.
The results1) show that ANYARA can be effectively combined with other established tumor therapies like docetaxel (Taxotere), bevacizumab (Avastin) and sunitinib (Sutent). ANYARA, combined with any of these products, had superior anti-tumor activity compared to single agent therapy.
ANYARA is presently developed primarily for the treatment of Renal Cell Cancer. A pivotal phase III study, which will encompass a total of 500 patients, is currently ongoing.
1) View the complete poster "A fusion protein between a 5T4 binding antibody fragment and an engineered superantigen (ANYARA) is a targeted immunotherapy effective alone and in combination with other cancer therapies" at www.activebiotech.com
About ANYARA
ANYARA is a TTS (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on renal cancer. Positive data was reported in connection with the interim analysis in Phase II/III and from clinical Phase I trials in lung cancer, renal cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cancer and treated with ANYARA is twice the expected length. Presently, pivotal Phase III trials in patients with advanced renal cancer are under way. The primary clinical efficacy parameter from this study is overall survival and it will include a total of approximately 500 patients at about 50 clinics in Europe. ANYARA has been granted orphan-drug status by the EMEA for the indication renal cancer. Information concerning the ongoing clinical study is available at www.activebiotech.com and www.clinicaltrials.gov.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI), headquartered in Sweden, is a biotechnology company with R&D focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information.
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on December 10, 2008, at 08:30 a.m.
SOURCE: Active Biotech AB
Post Views: 83
